Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
Crossref DOI link: https://doi.org/10.1007/s00280-017-3420-8
Published Online: 2017-08-30
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Skubitz, Keith M. http://orcid.org/0000-0002-0690-9595
Blaes, Anne H.
Konety, Suma H.
Francis, Gary S.
License valid from 2017-08-30